← Back to Search

Unknown

Rifampin effect on camlipixant pharmacokinetics for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bellus Health Inc. - a GSK company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Healthy males or non-pregnant, non-lactating healthy females

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre dose to up to 48 hours post-dose

Awards & highlights

Study Summary

This trial looks at how a tablet affects healthy people after taking rifampin & rabeprazole. It tests the drug BLU-5937 with a single dose.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre dose to up to 48 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre dose to up to 48 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre dose to up to 48 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Measurement of the area under the plasma concentration by time curve (AUC0-inf)

Measurement of the area under the plasma concentration by time curve (AUC0-t)

Measurement of the maximum observed plasma drug concentration (Cmax)

Trial Design

2Treatment groups

Experimental Treatment

Group I: Rifampin effect on camlipixant pharmacokineticsExperimental Treatment1 Intervention

Group II: Rabeprazole effect on camlipixant pharmacokineticsExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Camlipixant + Rifampin

2023

Completed Phase 1

~40

Camlipixant + Rabeprazole

2023

Completed Phase 1

~40

0 / 1Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bellus Health Inc. - a GSK companyLead Sponsor

17 Previous Clinical Trials

5,306 Total Patients Enrolled

Bellus Health IncLead Sponsor

15 Previous Clinical Trials

5,240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the eligibility criteria of this medical experiment restricted to individuals below a certain age?

"According to the terms of this medical trial, all participants must be over 18 years old and under 55 in order to qualify."

Answered by AI

What adverse consequences could arise from the combined use of rifampin and camlipixant?

"Considering the current evidence, our team at Power has rated Rifampin's effect on camlipixant pharmacokinetics with a 1. This is because this Phase 1 trial only gathered limited data to prove efficacy and safety."

Answered by AI

Who can enroll in this trial and fulfill the requirements?

"Qualified applicants should be in peak health and between the ages of 18 to 55. 32 people will participate in this trial."

Answered by AI

Is recruitment currently available for this trial?

"Per the information found on clinicaltrials.gov, it appears that this medical trial is not currently searching for participants since its last update was June 2nd 2023. Even though recruitment has concluded here, there are still 802 other studies actively recruiting patients at present time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

2023. "Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05899829.